World Library  
Flag as Inappropriate
Email this Article

Cannabidivarin

Article Id: WHEBN0001232351
Reproduction Date:

Title: Cannabidivarin  
Author: World Heritage Encyclopedia
Language: English
Subject: Effects of cannabis, Cannabinoid, Cannabidiol, URB754, PTI-1
Collection: Cannabinoids, Natural Phenols, Resorcinols
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cannabidivarin

Cannabidivarin
Systematic (IUPAC) name
2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)
cyclohex-2-enyl)-5-propylbenzene-1,3-diol
Identifiers
CAS Registry Number  N
ATC code None
DrugBank  N
ChemSpider  Y
Chemical data
Formula C19H26O2
Molecular mass 286.41 g/mol
 N   

Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis. It is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Plants with relatively high levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal.[1][2] CBDV has anticonvulsant effects.[3]

Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers (see: Cannabidiol#Double bond isomers and their stereoisomers). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals[4] (as GWP42006)because of a demonstrated neurochemical pathway for previously-observed anti-epileptic and anti-convulsive action.[5] GW has begun a phase 2 trial for adult epilepsy.[6]

See also

References

  1. ^ Turner, C.E., P. C. Cheng, G.S. Lewis, M.H.Russell and G.K. Sharma. 1979. Constituents of Cannabis sativa XV: Botanical and chemical profile of Indian variants. Planta medica 37(3): 217-225.
  2. ^ Hillig, Karl W. and Paul G. Mahlberg. 2004. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). American Journal of Botany 91(6): 966-975.
  3. ^ http://www.ncbi.nlm.nih.gov/pubmed/22970845
  4. ^ http://www.gwpharm.com/therapeutic-areas.aspx
  5. ^ Amada, N; Yamasaki, Y; Williams, C. M.; Whalley, B. J. (2013). "Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression". PeerJ 1: e214.  
  6. ^ plc, GW Pharmaceuticals. "GW Pharmaceuticals Initiates Phase 2 Clinical Study of Cannabidivarin (CBDV) in Epilepsy". Retrieved 2015-09-19. 

External links

  • Erowid Compounds found in Cannabis sativa


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.